About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ARNA
- CUSIP: 04004710
- Previous Close: $1.47
- 50 Day Moving Average: $1.47
- 200 Day Moving Average: $1.56
- 52-Week Range: $1.34 - $2.16
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.60
- P/E Growth: 0.21
- Market Cap: $377.14M
- Outstanding Shares: 243,313,000
- Beta: -0.64
- Net Margins: -197.50%
- Return on Equity: -336.85%
- Return on Assets: -39.53%
Companies Related to Arena Pharmaceuticals:
- Debt-to-Equity Ratio: 15.40%
- Current Ratio: 2.23%
- Quick Ratio: 2.06%
What is Arena Pharmaceuticals' stock symbol?
Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."
Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2017?
7 analysts have issued 1-year price targets for Arena Pharmaceuticals' shares. Their forecasts range from $1.50 to $6.00. On average, they anticipate Arena Pharmaceuticals' stock price to reach $3.75 in the next year.
When will Arena Pharmaceuticals announce their earnings?
Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Arena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October. However, sales of Belviq have been lackluster so far and are yet to pick up significantly. We are encouraged by the company’s decision to shift its priorities to its proprietary clinical-stage pipeline. Notably, Arena’s pipeline consists of early-to-mid stage candidates which are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players. Arena’s share price has also underperformed the industry in last three months. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/25/2017)
FBR & Co analysts commented, "We are initiating coverage of Arena Pharmaceuticals, Inc. (ARNA) with an Outperform rating and a 12-month price target of $6 per share. Historically, ARNA focused on obesity with its one approved drug, Belviq (lorcaserin). However, given the company’s expertise in discovery and drug development targeting G protein- coupled receptors (GPCRs), it is now primarily focused on advancing the pipeline with (1) etrasimod (APD334), a S1P receptor modulator for the potential treatment of ulcerative colitis (UC); (2) ralinepag, a prostacyclin receptor (PGI2) agonist for the potential treatment of pulmonary arterial hypertension (PAH); and (3) APD371, a cannabinoid receptor 2 (CB2) agonist in development for GI pain associated with Crohn’s disease." (9/15/2016)
Who owns Arena Pharmaceuticals stock?
Arena Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock, Inc (7.80%), Renaissance Technologies LLC (3.09%), State Street Corp (2.56%), FMR LLC (2.46%), Senzar Asset Management LLC (0.77%) and Oxford Asset Management (0.28%). Company insiders that own Arena Pharmaceuticals stock include Christine Anna White, Randall E Woods and Steven W Spector.
Who sold Arena Pharmaceuticals stock? Who is selling Arena Pharmaceuticals stock?
Arena Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Metropolitan Life Insurance Co. NY.
Who bought Arena Pharmaceuticals stock? Who is buying Arena Pharmaceuticals stock?
Arena Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Renaissance Technologies LLC, Oxford Asset Management, State Street Corp, A.R.T. Advisors LLC and Tudor Investment Corp Et Al.
How do I buy Arena Pharmaceuticals stock?
Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Arena Pharmaceuticals stock cost?
One share of Arena Pharmaceuticals stock can currently be purchased for approximately $1.57.